These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24340348)

  • 21. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualizing care with injectable glucose-lowering agents.
    Miller EM
    J Fam Pract; 2013 Dec; 62(12 Suppl CME):S12-9. PubMed ID: 24340344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical applications of therapy with a glucagon-like peptide-1 receptor agonist.
    Shomali ME
    J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S35-43. PubMed ID: 19744424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future of incretin-based therapy: novel avenues--novel targets.
    Ahrén B
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2014 Aug; 10(439):1549-54. PubMed ID: 25272672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J
    Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes.
    Schwartz SS; DeFronzo RA; Umpierrez GE
    Postgrad Med; 2015 Mar; 127(2):251-7. PubMed ID: 25547241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incretin-based therapies: review of current clinical trial data.
    Peters A
    Am J Med; 2010 Mar; 123(3 Suppl):S28-37. PubMed ID: 20206729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S5-9. PubMed ID: 20824239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus.
    Goldman-Levine JD
    Pharmacotherapy; 2011 Dec; 31(12 Suppl):44S-53S. PubMed ID: 22122222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL
    Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting among ADA/EASD tier 1 and tier 2 treatment options.
    McGill JB
    J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S26-34. PubMed ID: 19744422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.